- ADJUNCT ASSOCIATE PROFESSOR Medicine, General Internal Medicine
Abreu MT. Nod2 in normal and abnormal intestinal immune function. Gastroenterology 2005 October; 129(4): 1302-1304.
Abreu MT. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2005 May; 2(5): 210-211.
Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Design issues and outcomes in IBD clinical trials [review]. Inflamm Bowel Dis 2005 November; 1: S22-28.
Rochester J, Abreu MT. Ulcerative colitis therapy: importance of delivery mechanisms [review]. Rev Gastroenterol Disord 2005 Fall; 5(4): 215-222.
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006 January; 40(1): 55-63.
Abreu MT. Serologies in Crohn's disease: can we change the gray zone to black and white?. Gastroenterology 2006 August; 131(2): 664-667.
Lichtenstein GR, Abreu M, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease [review]. Gastroenterology 2006 March; 130(3): 940-987.
Lichenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 March; 130(3): 935-939.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Abreu is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.